We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The University of Oxford has announced that it has begun the first study of the AstraZeneca (AZ)/Oxford coronavirus vaccine in children and young adults to evaluate if the inoculation is safe and effective in patients aged six to 17. Read More
In observance of Presidents’ Day, Drug Industry Daily will not be published Monday, Feb. 15. The next issue will be published Tuesday, Feb. 16. Read More
The European Commission said it has made legally binding an agreement by Aspen Pharma to cut prices for six cancer drugs it markets in Europe by an average of 73 percent. Read More
The latest annual reports from the FDA’s Office of Pharmaceutical Quality (OPQ) and its Office of Generic Drugs (OGD) both highlight the impact of the COVID-19 pandemic on their activities in the past year. Read More
Fresenius Kabi Oncology (FKO) has agreed to plead guilty to hiding and destroying records prior to a 2013 FDA inspection and will hand over $50 million in fines and forfeiture, the U.S. Department of Justice revealed. Read More
AstraZeneca said it is “exploring options” with German manufacturer IDT Biologika to boost the supply of its vaccine in Europe during the second quarter of the year. Read More
A Government Accountability Office (GAO) review of COVID-19 vaccine development efforts found that vaccine producers are facing significant manufacturing hurdles as they scale up operations. Read More
The House Energy and Commerce Committee has approved a one-time $500 million in additional FDA funding for coronavirus-related support as part of the COVID-19 relief package currently making its way through the Congress. Read More
The U.S. government has purchased 100 million additional doses of both the Pfizer/BioNTech and Moderna messenger RNA (mRNA)-based COVID-19 vaccines in an effort by the Biden administration to ramp up inoculations. Read More
Pharma giants Teva Pharmaceuticals and Merck are currently in talks about adding their significant manufacturing capabilities to COVID-19 vaccine production, though specifics have not been disclosed at this point. Read More